Business Context and Reporting Period
This Form 8-K was filed by iBio, Inc. on December 20, 2018. The report addresses the company's status regarding its listing on the NYSE American.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report references a prior deficiency related to stockholders' equity being less than $6,000,000 combined with sustained losses, but does not disclose current financial figures.
Material Changes
On December 20, 2018, iBio, Inc. was formally notified by the NYSE American that it has regained compliance with all continued listing standards. Specifically, the company resolved the deficiency under Section 1003(a)(iii) of the NYSE American Company Guide, which pertains to stockholders' equity and sustained losses.
Outlook and Management Commentary
The company had previously submitted a plan of compliance on August 16, 2018, to address the listing deficiency by December 6, 2019. The current filing confirms that the exchange has accepted the company's resolution of the issue, allowing it to maintain its listing. No forward-looking guidance or risk factors beyond the listing status are detailed in this specific report.
Investor Verification Checklist
- Verify the specific financial actions taken to resolve the stockholders' equity deficiency.
- Confirm the current stockholders' equity balance to ensure it meets the $6,000,000 threshold or other applicable standards.
- Review the company's most recent 10-K or 10-Q for detailed financial performance and loss history.
- Monitor future filings for any new compliance plans or listing warnings.